Wilcoxon testing (after 52 weeks of trial) further indicated a highly significant sex difference in the placebo groups (** P = 0.00867, Table S1 ), with the GDS score improving significantly in davunetide-treated females, as compared to the placebo group, at week 52 (* P = 0.0178, Fig. 3C and Table S1 ).
Female placebo group-associated neurodegeneration, reflected by the increase in brain ventricular volume, was directly correlated with the primary endpoints of the trial, i.e., SEADL scale ( r = −0.312*) and PSPRS (almost significant, r = 0.272.), as well as with the exploratory CGIds ( r = 0.405**), protection was seen in the davunetide-treated cohort (i.e., almost no correlation).